RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
Multinational Study of Vascular Disease in Diabetes. Diabet
Med 12: 149-155, 1995.
265. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving
HH: Albuminuria and poor glycemic control predict mortality
in NIDDM. Diabetes 44:1303-1309, 1995.
266. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K,
Laakso M: Proteinuria predicts stroke and other atherosclerotic
vascular disease events in nondiabetic and non-insulindependent
diabetic subjects. Stroke 27: 2033-2039, 1996.
267. Dinneen SF, Gerstein HC: The association of microalbuminuria
and mortality in non-insulin-dependent diabetes mellitus.
A systematic overview of the literature. Arch Intern Med
157: 1413-1418, 1997.
268. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular
disease mortality associated with microalbuminuria
and gross proteinuria in persons with older-onset diabetes
mellitus. Arch Inter Med 160: 1093-1100, 2000.
269. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor
of vascular disease in non-diabetic subjects. Islington
Diabetes Survey. Lancet 2: 530-533, 1998.
270. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE:
Microalbuminuria as predictor of increased mortality in
elderly people. BMJ 300: 297-300, 1990.
271. Wagner DK, Harris T, Madans JH : Proteinuria as a biomarker:
risk of subsequent morbidity and mortality. Environ Res
66: 160-172, 1994.
272. Kuusisto J, Mykkanen L, Pyorala K, Laakso
M:Hyperinsulinemic microalbuminuria. A new risk indicator
for coronary heart disease. Circulation 91: 831-837, 1995.
273. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary
albumin excretion – a predictor of risk of cardiovascular
disease. A prospective 10-year follow-up of middle-aged
nondiabetic normal and hypertensive men. Am J Hypertens
9: 770-778, 1996.
274. Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness
of microalbuminuria in predicting cardiovascular mortality
in treated hypertensive men with and without diabetes. Risk
Factor Intervention Study Group. Am J Cardiol 80: 164-169,
1997.
275. Grimm RJ, Svendsen K, Kasiske B, y cols. Proteinuria as a
risk factor for mortality over 10 years of follow-up. MRFIT
Research Group: Multiple Risk Factor Intervention Trial.
Kidney Int 63; S10-S14, 1997.
276. Bigazzi R, Bianchi S, Baldari D, Campese VM:
Microalbuminuria predicts cardiovascular events and renal
insufficiency in patients with essential hypertension. J
Hypertens 16: 1325-1333, 1998.
277. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker
JM, y cols. Microalbuminuria and peripheral arterial disease
are independent predictors of cardiovascular and all-cause
mortality, especially among hypertensive subjects: five-year
follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol
19: 617-624, 1999.
278. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll
M, Jensen JS: Urinary albumin excretion. An independent
predictor of ischemic heart disease. Arterioscler Thromb Vasc
Biol 19: 1992-1997, 1999.
279. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D:
Proteinuria as a risk factor for cardiovascular disease and
mortality in older people: a prospective study. Am J Med
109: 1-8, 2000.
280. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M,
Borch-Johnsen K: Arterial hypertension, microalbuminuria,
and risk of ischemic heart disease. Hypertension 35: 898-
903, 2000.
281. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia
G, Rosenthal T, y cols. Morbidity and mortality in patients
randomised to double-blind treatment with a long-acting
calcium-channel blocker or diuretic in the International
Nifedipine GITS study: Intervention as a Goal in
Hypertension Treatment (INSIGHT). Lancet 356: 366-372,
2000.
282. Roest M, Banga JD, Janssen WMT, Grobbee DE, Sixma JJ, de
Jong PE, y cols. : Excessive urinary albumin levels are associated
with future cardiovascular mortality in postmenopausal
women. Circulation 103: 3057-3061, 2001.
283. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ,
Grobbee DE, y cols. Microalbuminuria modifies the mortality
risk associated with electrocardiographic ST-T segment
changes. J Am Coll Cardiol 40: 1401-1407, 2002.
284. Gerstein HC, Mann JFF, Yi Q, Zinman B, Dinneen SF,
Hoogwerf B, y cols. for the HOPE Study Investigators:
Albuminuria and risk of cardiovascular events, death, and
heart failure in diabetic and nondiabetic individuals. JAMA
286: 421-426, 2001.
285. Hillege, HL, Fidler, V, Diercks, GF, van Gilst WH, de Zeeuw
D, van Veldhuisen DJ, y cols. for the Prevention of Renal and
Vascular End Stage Disease (PREVEND) Study Group:
Urinary albumin excretion predicts cardiovascular and noncardiovascular
mortality in general population. Circulation
106: 1777-1782, 2002.
286. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjær H:
Microalbuminuria and all-cause mortality in 2,089 apparently
healthy individuals: a 4.4-year follow-up study. The
Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney
Dis 42: 466-473, 2003.
287. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm
LH, Mogensen CE, y cols. Albuminuria and cardiovascular
risk in hypertensive patients with left ventricular hypertrophy:
the LIFE study. Ann Intern Med 139: 901-906, 2003.
288. Segura J, Campo C, Ruilope LM: Proteinuria: an underappreciated
risk factor in cardiovascular disease. Curr Cardiol Rep
4: 458-462, 2002.
289. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de
Faire U, y cols. for the LIFE study group: Cardiovascular morbidity
and mortality in the Losartan Intervention For
Endpoint reduction in hypertension study (LIFE): a randomised
trial against atenolol. Lancet 359: 995-1003, 2002.
290. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G,
de Faire U, y cols. for the LIFE study group: Cardiovascular
morbidity and mortality in patients with diabetes in the
Losartan Intervention For Endpoint reduction in hypertension
study (LIFE): a randomised trial against atenolol. Lancet 359:
1004-1010, 2002.
291. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B,
Hamm LL y cols. Kidney disease as a risk factor for development
of cardiovascular disease. A statement from the
American Heart Association Councils on kidney in cardiovascular
disease, high blood pressure research, clinical cardiology,
and epidemiology and prevention. Hypertension
42:1050-65, 2003.
292. Rigatto C. Clinical epidemiology of cardiac disease in renal
transplant recipients. Semin Dial 16: 106-110, 2003.
195